1.Prognostic Factors of Postherpetic Neuralgia.
Journal of Korean Medical Science 2002;17(5):655-659
The investigation was aimed to determine prognostic factors related to postherpetic neuralgia (PHN), and treatment options for preventing PHN. The data showed 34 (17.0%) out of 188 patients with herpes zoster had severe pain after 4 weeks, and 22 (11.7%) after 8 weeks, compared with 109 (58.0%) at presentation. The age (>or=50 yr), surface area involved (>or=9%), and duration of severe pain (>or=4 weeks) might be the main factors that lead to PHN. On the other hand, gender, dermatomal distribution, accompanied systemic conditions, and interval between initial pain and initiation of treatment might not be implicated in PHN. The subjects were orally received antiviral (valacyclovir), tricyclic antidepressant (amitriptyline), and analgesic (ibuprofen) as the standard treatment in the group 1. In addition to the standard medication, lidocaine solution was sub- and/or perilesionally injected in the group 2, while lidocaine plus prilocaine cream was topically applied to the skin lesions in the group 3. The rates of PHN in the 3 treatment groups were not significantly different, suggesting adjuvant anesthetics may not be helpful to reduce the severity of pain.
Acyclovir/administration & dosage/*analogs & derivatives
;
Adolescent
;
Adult
;
Aged
;
Amitriptyline/administration & dosage
;
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage
;
Antidepressive Agents, Tricyclic/administration & dosage
;
Antiviral Agents/administration & dosage
;
Child
;
Drug Therapy, Combination
;
Female
;
Herpes Zoster/*complications/drug therapy/physiopathology
;
Humans
;
Ibuprofen/administration & dosage
;
Male
;
Middle Aged
;
Neuralgia/drug therapy/*etiology/physiopathology/prevention & control
;
Prognosis
;
Time Factors
;
Valine/administration & dosage/*analogs & derivatives
2.Fibromyalgia Syndrome.
Journal of the Korean Neurological Association 2013;31(1):1-7
Fibromyalgia is a chronic pain syndrome of unknown etiology that is characterized by diffuse musculoskeletal pain, fatigue, sleep disturbance, memory disturbance, and exaggerated tenderness over particular paired locations. Fibromyalgia is found in 2% to 4% of the general population and more common in women, with symptoms usually appearing between 20 and 55 years of age. The diagnostic criteria for fibromyalgia syndrome established in 1990 by the American College of Rheumatology (ACR), includes widespread pain for at least 3 months and point tenderness upon the application of a 4 kg weight at 11 or more of the 18 characteristic tender points. The 2010 ACR preliminary diagnostic criteria have been developed, which are strongly correlated with the 1990 ACR criteria and provide an alternative approach to diagnosis. Patients with fibromyalgia syndrome have lower pain thresholds and experience an altered temporal summation to pain stimuli. The sensitization of pain perception occurs in the dorsal horn of patients with fibromyalgia. However, it is unknown whether sensitization is due to increased pain fiber facilitation, or decreased inhibition. Pregabalin is approved by the United States Food and Drug Administration for the management of fibromyalgia patients. Tricyclic antidepressants, cardiovascular exercise, cognitive behavioral therapy and patient education are also effective in reducing the pain experienced by fibromyalgia patients. This article provides an overview of fibromyalgia syndrome, which is currently thought to be partly responsible for chronic diffuse pain.
Animals
;
Antidepressive Agents, Tricyclic
;
Chronic Pain
;
Cognitive Therapy
;
Fatigue
;
Female
;
Fibromyalgia
;
gamma-Aminobutyric Acid
;
Horns
;
Humans
;
Memory
;
Musculoskeletal Pain
;
Pain Perception
;
Pain Threshold
;
Patient Education as Topic
;
Rheumatology
;
United States Food and Drug Administration
;
Pregabalin